Elekta (OTCMKTS:EKTAY) Sets New 12-Month High – What’s Next?

Elekta AB (OTCMKTS:EKTAY)’s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $6.32 and last traded at $6.32, with a volume of 435 shares. The stock had previously closed at $6.2750.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 16th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Elekta Stock Up 0.7%

The company has a debt-to-equity ratio of 0.66, a current ratio of 1.04 and a quick ratio of 0.79. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of 90.30 and a beta of 1.04. The firm’s 50-day moving average is $5.49 and its 200 day moving average is $5.19.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings data on Wednesday, November 26th. The company reported $0.07 earnings per share (EPS) for the quarter. The company had revenue of $427.85 million during the quarter, compared to analysts’ expectations of $436.91 million. Elekta had a net margin of 1.62% and a return on equity of 12.14%. Sell-side analysts anticipate that Elekta AB will post 0.36 earnings per share for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.